SUSTAINED RESPONSE IN A PHASE III STUDY OF SARILUMAB PLUS NONBIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH ACTIVE, MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO TUMOR NECROSIS FACTOR INHIBITORS

被引：0
|
作者：
Fleischmann, Roy [1 ]
St John, Greg [2 ]
Kimura, Toshio [3 ]
Iglesias-Rodriguez, Melitza [4 ]
Rosner, Itzhak [5 ]
Burmester, Gerd R. [6 ,7 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Metroplex Clin Res Ctr, Dallas, TX 75390 USA
[2] Regeneron Pharmaceut Inc, Med Affairs, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[3] Regeneron Pharmaceut Inc, Med Affairs, Med Analyt, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[4] Sanofi Genzyme, Global Med Affairs, Cambridge, MA USA
[5] Bnai Zion Med Ctr, Div Allergy & Clin Immunol, Haifa, Israel
[6] Free Univ, Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany
[7] Humboldt Univ, Berlin, Germany
来源：
RHEUMATOLOGY | 2018年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
223
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Tofacitinib (CP-690,550) in Combination with Traditional Disease-Modifying Anti-Rheumatic Drugs: Phase 3 Study Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis and An Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs.
    Strand, V.
    Kremer, J. M.
    Li, Z. G.
    Hall, S.
    Fleischmann, Roy M.
    Genovese, M. C.
    Martin-Mola, E.
    Isaacs, J.
    Gruben, D.
    Wallenstein, G.
    Krishnaswami, S.
    Zwillich, S. H.
    Koncz, T.
    Riese, R.
    Bradley, J. D.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S1032 - S1032
  • [22] TREATMENT PATTERNS, PERSISTENCE, AND DURABILITY IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS)
    Dore, Robin K.
    Antonova, Jenya
    Burudpakdee, Chakkarin
    Wang, Xin
    Ozbay, Burak
    Genovese, Mark C.
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1135 - 1136
  • [23] SUSTAINABILITY OF RESPONSE TO UPADACITINIB AMONG PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    van Vollenhoven, Ronald
    Hall, Stephen
    Wells, Alvin F.
    Meerwein, Sebastian
    Song, Yanna
    Suboticki, Jessica L.
    Fleischmann, Roy
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 29 - 30
  • [24] Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs
    van Vollenhoven, Ronald
    Hall, Stephen
    Wells, Alvin
    Meerwein, Sebastian
    Song, Yanna
    Suboticki, Jessica
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3534 - 3536
  • [25] SUSTAINABILITY OF RESPONSE TO UPADACITINIB AMONG PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Van Vollenhoven, R.
    Hall, S.
    Wells, A. F.
    Meerwein, S.
    Song, Y.
    Suboticki, J.
    Fleischmann., R. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1290 - 1291
  • [26] Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study
    Yazici, Yusuf
    Curtis, Jeffrey R.
    Ince, Akgun
    Baraf, Herbert
    Malamet, Raymond L.
    Teng, Lichen L.
    Kavanaugh, Arthur
    ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (02) : 198 - 205
  • [27] COMPARISON OF TOCILIZUMAB AS MONOTHERAPY OR WITH ADD-ON DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO PREVIOUS TREATMENTS
    Tymms, K.
    Littlejohn, G.
    Bossingham, D.
    Griffiths, H.
    Bagga, H.
    Clemens, L.
    Smith, M.
    Bird, P.
    Mpofu, C.
    Bernasconi, C.
    Bykerk, V.
    INTERNAL MEDICINE JOURNAL, 2012, 42 : 13 - 14
  • [28] EFFICACY AND SAFETY OF UPADACITINIB IN A CHINESE SUBGROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Zeng, X.
    Liu, Y.
    Hu, J.
    Li, J.
    Wang, Y.
    Zhao, D.
    Wu, L.
    Xiao, Z.
    Li, Z.
    Xu, J.
    Meerwein, S.
    Xie, Y.
    Liang, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1324 - 1324
  • [29] FAVORABLE EFFECTS OF SIRUKUMAB TREATMENT ON PHYSICAL FUNCTION AND REDUCTIONS IN MORNING STIFFNESS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Thorne, C.
    Takeuchi, T.
    Karpouzas, G.
    McQuarrie, K.
    Sheng, S.
    Xu, W.
    Peterson, S.
    Ganguly, R.
    Han, C.
    Fei, K.
    Hsu, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1018 - 1019
  • [30] Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
    Muszbek, Noemi
    Proudfoot, Clare
    Fournier, Marie
    Chen, Chieh-I
    Kuznik, Andreas
    Kiss, Zsofia
    Gal, Peter
    Michaud, Kaleb
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (11): : 1268 - 1280
12345